Ketorolac 60 mg Injection is the highest injectable strength of ketorolac tromethamine, designed for short‑term management of severe acute pain. Unlike lower strengths, the 60 mg dose is administered exclusively intramuscularly (IM), providing rapid systemic absorption and strong non‑opioid analgesia. It is typically used in clinical environments where fast, decisive pain control is required, such as trauma care, postoperative recovery, and emergency settings.
As a potent NSAID, ketorolac offers fast onset and a moderate duration of action, but its use is intentionally limited to short courses due to its safety profile. This page provides an overview of how the 60 mg injection works, when it is used, and how it compares with lower strengths such as Ketorolac 30 mg. For broader information on injectable Toradol, visit the Toradol injection page.
Ketorolac 60 mg Injection is the highest injectable strength of ketorolac tromethamine, a potent nonsteroidal anti-inflammatory drug (NSAID) used for short-term management of severe acute pain. Unlike lower strengths, the 60 mg dose is administered exclusively intramuscularly (IM), providing rapid systemic absorption without the need for intravenous access. This formulation is typically used in clinical environments such as emergency departments, trauma care, and postoperative recovery units where strong, fast-acting non-opioid analgesia is required. As the maximum-strength injectable dose, it offers intense initial pain relief when lower doses may be insufficient.
Ketorolac 60 mg works by inhibiting prostaglandin synthesis, reducing inflammation and decreasing pain receptor sensitivity. This mechanism is characteristic of NSAIDs but is more pronounced in ketorolac due to its potency. The IM route provides a fast onset because the medication is absorbed efficiently through muscle tissue. Despite its strong effect, ketorolac is used only short-term because prolonged prostaglandin inhibition increases gastrointestinal and renal risks. The 60 mg dose differs from lower strengths by offering a higher initial analgesic intensity, making it suitable for severe pain scenarios where rapid stabilization is essential.
Ketorolac 60 mg Injection is used for short-term management of severe acute pain when rapid and strong non-opioid analgesia is required. It is commonly administered after major surgical procedures, particularly when postoperative pain is intense and immediate relief is necessary. The high potency of the 60 mg dose makes it suitable for situations where lower strengths may not provide adequate stabilization.
This dose is also used in trauma-related pain, including fractures, severe sprains, and musculoskeletal injuries. In emergency settings, the fast onset of IM ketorolac allows clinicians to quickly reduce pain intensity while further evaluation or treatment is underway. More information on pain-related use cases is available on the Toradol for pain page.
In some clinical environments, ketorolac injections may be used for acute migraine episodes when rapid non-opioid analgesia is needed. Additional details can be found on the Toradol for migraine page.
Although the 60 mg dose is used less frequently than 30 mg, it remains important in cases where stronger initial analgesia is required. Its use is more selective because it carries a higher systemic load, but it remains a valuable option for severe pain scenarios where rapid stabilization is essential.
Ketorolac 60 mg is administered exclusively intramuscularly (IM). This route delivers the medication deep into muscle tissue, where it is absorbed efficiently into systemic circulation. IM administration is chosen for the 60 mg dose because it provides strong, rapid analgesia without the need for intravenous access, making it suitable for emergency and trauma settings.
The 60 mg dose is not used intravenously (IV) because its higher concentration is intended for controlled IM absorption rather than immediate IV delivery. IV administration is typically reserved for lower strengths such as 30 mg, which offer a more balanced onset and systemic exposure. A detailed comparison of IM and IV routes is available on the Toradol IM vs IV page.
The onset of IM ketorolac 60 mg is fast, though slightly slower than IV administration of lower doses. However, the overall analgesic intensity is higher due to the increased amount of active ingredient. This makes the 60 mg dose suitable for severe pain scenarios where rapid stabilization is essential.
Ketorolac 60 mg has a fast onset when administered intramuscularly. IM absorption allows the medication to enter systemic circulation efficiently, producing rapid analgesic effects. Although IM onset is slightly slower than IV administration of lower doses, the overall intensity of pain relief is higher due to the increased amount of active ingredient.
The injectable form works significantly faster than oral tablets because it bypasses the digestive system and first-pass metabolism. This makes ketorolac injections ideal for severe acute pain scenarios where rapid stabilization is required. More information about onset differences is available on the Toradol onset & duration page.
Factors influencing onset include muscle perfusion, patient circulation status, and the severity of the underlying condition. Regardless of these variables, ketorolac 60 mg consistently provides fast, strong analgesia in clinical settings.
Ketorolac 60 mg provides a moderate duration of analgesia, long enough to manage severe acute pain episodes but not intended for prolonged therapy. The duration is similar to lower injectable strengths because ketorolac’s elimination profile remains consistent regardless of dose.
The effect is intentionally limited due to safety considerations. Prolonged prostaglandin inhibition increases the risk of gastrointestinal irritation, ulcers, bleeding, and kidney stress. For this reason, ketorolac injections—including the 60 mg dose—are used only short-term and are not suitable for chronic pain management.
The moderate duration makes Ketorolac 60 mg ideal for rapid stabilization followed by transition to oral therapy if continued analgesia is needed.
Ketorolac injections are available in several strengths, with 20 mg, 30 mg, and 60 mg being the most common. The 60 mg dose is the maximum injectable strength and is used when severe acute pain requires strong, rapid analgesia. It is administered exclusively intramuscularly and provides the highest initial intensity of pain relief.
The Ketorolac 30 mg injection is the standard hospital dose, offering a strong balance of rapid onset, moderate duration, and broad clinical applicability. It is used for most postoperative and trauma-related pain scenarios.
The Ketorolac 20 mg dose is an intermediate option, providing strong analgesia with a slightly lower systemic load. It is used when clinicians want rapid relief but prefer a more conservative dose than 30 mg.
The 60 mg dose is considered the “maximum” injectable strength because it delivers the highest systemic exposure and strongest initial analgesic effect. It is used selectively in severe pain scenarios where lower doses may not be sufficient. Its use is less common but remains essential for cases requiring decisive, fast-acting non-opioid pain control.
Ketorolac 60 mg Injection is selected when rapid, high‑intensity analgesia is required, particularly in severe acute pain scenarios where lower doses or oral medications would act too slowly. Because the 60 mg dose is administered intramuscularly (IM), it provides fast systemic absorption and strong non‑opioid pain relief. This makes it suitable for trauma, postoperative pain, and emergency situations where immediate stabilization is essential.
Toradol Oral, described on the Toradol oral page, is used after the acute phase has been controlled. Tablets have a slower onset because they must be absorbed through the gastrointestinal tract, but they offer a convenient way to maintain analgesia once the patient no longer requires injectable therapy.
The onset of the 60 mg injection is fast, while the onset of tablets is moderate. Duration is similar across both forms, but injections—especially the 60 mg dose—are reserved for short-term use due to their potency and systemic impact. The typical clinical sequence is “injection → tablets,” where Ketorolac 60 mg provides rapid initial relief, followed by oral ketorolac for continued short-term pain control.
Ketorolac 60 mg Injection shares the same side‑effect profile as other ketorolac formulations, but its higher strength makes these effects more pronounced. Common side effects include nausea, stomach discomfort, dizziness, and headache. Because ketorolac strongly inhibits prostaglandins, it may irritate the gastrointestinal lining, increasing the risk of stomach pain or indigestion.
More serious risks include gastrointestinal bleeding, ulceration, and kidney stress. Prostaglandins help protect the stomach and support renal blood flow, so strong inhibition can lead to complications when ketorolac is used for extended periods. These risks apply to all injectable strengths, but the 60 mg dose carries a higher systemic load, reinforcing the need for short-term use.
Because the 60 mg dose is administered intramuscularly, local reactions may include soreness, swelling, or discomfort at the injection site. These effects are generally mild compared with the systemic risks associated with prolonged prostaglandin inhibition.
Limiting the duration of therapy is essential. Ketorolac is a high-potency NSAID, and short-term use helps reduce the likelihood of gastrointestinal and renal complications, ensuring that the medication provides strong analgesia without unnecessary risk.
Ketorolac 60 mg Injection is contraindicated in individuals with active gastrointestinal ulcers, recent GI bleeding, or a history of perforation, as its strong prostaglandin inhibition can worsen these conditions. It is also avoided in patients with severe kidney impairment, since reduced renal blood flow may further compromise kidney function.
Age-related considerations apply as well. Older adults may be more susceptible to gastrointestinal and renal side effects, and clinicians often use caution when prescribing ketorolac in this population. The medication is intended strictly for short-term use, and prolonged therapy is avoided to reduce the likelihood of serious complications.
Combining ketorolac with other NSAIDs is generally avoided because it increases the risk of gastrointestinal irritation, kidney stress, and bleeding. Caution is also required in individuals with bleeding disorders, dehydration, cardiovascular risk factors, or conditions that may worsen with prostaglandin inhibition.
| Parameter | Value |
|---|---|
| Form | Injection |
| Dosage | 60 mg |
| Route | IM |
| Onset | Fast |
| Duration | Moderate |
| Use | Severe acute pain |
Ketorolac 60 mg is the maximum injectable strength used for severe acute pain. It provides a fast onset and moderate duration, making it suitable for trauma, postoperative pain, and emergency care. Because of its high potency, it is used selectively and only for short-term stabilization before transitioning to lower doses or oral therapy.
| Dosage | Route | Onset | Duration | Where Used |
|---|---|---|---|---|
| 20 mg | IM / IV | Fast | Moderate | Acute pain |
| 30 mg | IM / IV | Fast | Moderate | Standard dose |
| 60 mg | IM | Fast | Moderate | Severe pain |
All three injectable strengths provide fast onset and moderate duration, but they differ in intensity and clinical use. The 20 mg dose is an intermediate option, the 30 mg dose is the standard hospital strength, and the 60 mg dose is reserved for severe pain requiring strong initial analgesia. Each strength is selected based on the severity of pain and clinical judgment.
| Form | Onset | Duration |
|---|---|---|
| Injection | Fast | Moderate |
| Nasal | Fast | Moderate |
| Oral | Moderate | Moderate |
Toradol injections provide the fastest onset because they enter systemic circulation quickly. Nasal spray also acts rapidly by bypassing the digestive system. Oral tablets have a slower onset due to gastrointestinal absorption, but all forms share a similar moderate duration. These differences guide clinical decisions when selecting the appropriate form for acute pain management.